Broomfield, Colo. – August 7, 2014 – Cooley LLP announced today that it advised GlobeImmune, Inc. (GBIM) on its IPO. GlobeImmune is a biopharmaceutical company focused on the development of products designed for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. The company trades on the NASDAQ Capital Market under the symbol "GBIM."
Thus far in 2014, Cooley has advised on 73 public offerings, including 37 completed IPOs.
About Cooley LLP
Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.
Cooley has more than 750 lawyers across 11 offices in the United States and China.